Cargando…
Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study
BACKGROUND: Minor adverse event following immunizations (AEFIs) are often underreported and self-treated. This study aimed to collect information regarding any and every probable adverse event experienced by the recipient of Covishield vaccine up to 10 days following the first and second dose of vac...
Autores principales: | Velhal, Gajanan D., Kamath, Yash V., Agrawal, Ansh S., Vora, Devanshi S., Dwivedi, Vaibhav R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891042/ https://www.ncbi.nlm.nih.gov/pubmed/36742958 http://dx.doi.org/10.4103/ijcm.ijcm_93_22 |
Ejemplares similares
-
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022) -
Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022) -
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022) -
Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022) -
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022)